Økonomisk Ugebrev 21st of April 2021 Henrik Winther, SVP BD

BI ·· VICA

Unmet needs in Metastatic Breast Cancer

From a treatment perspective:

- Efficient tool to allow for <u>faster and better</u> treatment (Tx)

 incl. tool to <u>ID Tx-resistance</u> as early as possible
- Tool to allow for <u>confidence</u> in choosing the right treatment / <u>avoiding</u> futile therapy


From a monitoring perspective:

- <u>Avoidance</u> of invasive and radiation-based tests
- <u>Reduction</u> in number and costs of diagnostic tests



BI ·· VICA

DiviTum®TKa provides easy, early and safe response to whether or not the patient's cancer treatment is effective



DiviTum®TKa measures cell proliferation rate in a blood sample for faster evaluation of cancer treatment effects

References: See http://biovica.com/technology/publications/


Very strong clinical results and data for DiviTum®TKa peer- BI⊕VICA reviewed & published in clinical oncology journals

- 24 published and peer-reviewed articles with DiviTum®TKa
- Summary of results from articles:
 - Prognostic: risk for cancer recurrence, progression & survival
 - Monitoring: quick feedback on treatment efficacy

Cancer area	Patients	No of Studies	
Rreast Cancer	1,293	13	>
🞗 Gastrointestinal	713	4	
🕺 Lung Cancer	281	2	
🞗 Blood Cancer	440	4	
S Other	368	1	
	3,095	24	



DiviTum®TKa – Extensive breast cancer study program




BI ·· VICA

BI ··VICA

SABCS 2020 DiviTum®TKa studies, conclusions, and the fit to clinical needs & clinical utility

STUDY / COLLABORATOR	CONCLUSION	TKa CLINICAL UTILITY
S0226 / SWOG	 TKa PROGNOSTIC for PFS/OS in mBC TKa PREDICTIVE for treatment (Tx) in mBC TKa strong MONITOR of mBC during Tx 	 Strong liquid* biomarker to monitor mBC during endocrine Tx Treatment prediction * Avoid invasive- & radiation-based tests
PALBO-DOSING /WASH.U.	 TKa strong MONITOR of CDK 4/6 Tx in mBC TKa detects cancer progression 3 mths earlier than imaging during CDK 4/6 Tx in mBC 	 Confidence in right Tx Reduction in diagnostic (imaging) testing
PYTHIA / BIG & IBCSG (Prospective)	 TKa is an early and strong PREDICTOR of CDK 4/6 Tx 	Avoidance of CDK 4/6 futile therapyFaster and better Tx
No. X		

Results and consequences of the Wash. U. study BI⊕VICA - imaging scan reduction and replacement with DiviTum®TKa



In patients with persistently low TKa values, DiviTum®TKa may offer the opportunity to reduce imaging scan frequency

Market potential & geographical roll-out plan for DiviTum®TKa in metastatic breast cancer

1. US LAUNCH **CLINICAL USAGE & UPTAKE** Market potential: 200-350 mUSD TOTAL MARKET POTENIAL 2. EU-5 & NORDICS **CLINICAL USAGE & UPTAKE** 400-700 Market potential: 150-250 mUSD MMERCIAL PARTNERING **mUSD** 3. JAPAN **CLINICAL USAGE & UPTAKE** Market potential: 50–100 mUSD 4. ROE & ROW **CLINICAL USAGE & UPTAKE** 60% of breast cancer patients at lower price Source: (1) Globocan 2018 and Biovica Market Research

BI ·· VICA


DiviTum®TKa – US commercialization activities & status



BI ·· VICA

BI ·· VICA

FDA resumed its review of the 510(k) application



- 25th Sep: 510(k) application submitted to the FDA Lead reviewer assigned
- 30th Oct: FDA announces 90 day-pause due to resource allocation Lead reviewer reallocated to review of Covid-related EUA
- 13th Nov: Substantive Review status received from the FDA
- 29th Jan: FDA resumes review of DiviTum®Tka 510(k)-application Lead reviewer re-assigned Note: FDA doesn't commit their standard 510(k)-timeline
- Status: FDA review is ongoing Biovica expects decision before end of Q3


Source: https://www.fda.gov/medical-devices/premarket-notification-510k/510k-submission-process#timeline

COMMERCIAL PARTNERING

BI⊕VICA

Focus on key cancer centers, reference labs, IDNs & payers

71 NCI-designated cancer centers



Major reference laboratories

Company	# of labs	Oncology labs
LabCorp	31	2
Quest Diagnostics*	32	5
SONIC HEALTHCARE	11	2
BioReference	16	1
MAYO CLINIC LABORATORIES	2	2
	1	1
	8	8
Cleveland Clinic	1	1

IDNs/Payers KAISER PERMANENTE®

Geisinger Health Plan

UnitedHealthcare®

Anthem 👁 🕅

These will be customers and at the same time, partners

GUIDELINES & REIMBURSEMENT

BI ·· VICA

Key Opinion Leader Collaborators

- key success factor for clinical acceptance/guidelines/reimbursement



Matthew P. Goetz M.D Mayo Clinic



Daniel F. Hayes M.D, Professor University of Michigan Ex. ASCO President SWOG Transl. Med.



Vered Stearns



Geoffrey Shapiro





Martine J. Piccart M.D, Professor Université Libre de Bruxelles Founder Big against BC Ex. ESMO President



M.D & Professor Johns Hopkins



M.D, Ph.D Dana Farber



Jonas Bergh M.D, Professor Karolinska Institutet ESMO BC Award Ex Chairman SweBCG EMA Advisory Group Member Nobel Assembly

Angelo Di Leo

Hospital of Prato

IBCSG Exec. Committee

BIG against BC Exec Board

ESMO Lifetime Achievement

M.D, Ph.D



Luca Malorni M.D, Ass. Professor Hospital of Prato Baylor Collage



Matthew J. Ellis M.D, Professor Baylor Collage



William Gradishar M.D, Professor Northwestern Med.



Thomas Hatschek M.D, PhD Karolinska Institutet



Samuel Rotstein M.D, PhD Karolinska Sjukhuset



Cynthia X. Ma M.D, Professor Washington University



Henrik Lindman M.D, Ass. Professor Uppsala Universitet Vice Chairman SweBCG



Sacha Howell M.D, PhD Senior Lecturer and Honorary Consultant in Medical Oncology The Christie NHS Foundation Trust

GUIDELINES & REIMBURSEMENT

BI ·· VICA

US product reimbursement process in execution

Evidence	Initiated			
development	Payers	Running full sp	eed Initiated	
(High impact	engagement	Guideline		CLINICAL USAGE &
publications)	(Coverage)	inclusion	Coding,	UPTAKE
		(TKa ambassa- dors through	Pricing, Billing & Payment	
	_	KOL network)		
		,	(Coding strategy)	

GUIDELINES & REIMBURSEMENT

BI ·· VICA

DiviTum®TKa budget impact model

- adding DiviTum[®]TKa saves up to three times the investment


Parameters of Interest							
Monitoring Frequencies	DiviTum® Testing	< CT Scans > <u>Pre-DiviTum®</u> Post-DiviTu		Scans > Post-DiviTum®		arkers > <u>Post-DiviTum®</u>	
Monitoring Technology On/Off	On	On On	On	On	On	On	
Time Until First Follow-Up	2 weeks	12 weeks 12 week	ts 12 weeks	12 weeks	4 weeks	4 weeks	
Subsequent Follow-Up Period 1 Interval Unit # Follow-Ups for Subs Period 1 Subsequent Follow-Up Period 2 Interval Unit # Follow-Ups for Subs Period 2	Monthly 6 Quarterly 6	QuarterlySemi-Annua21QuarterlySemi-Annua63	2	Se \$13600 \$13400 \$13200 \$13000			
• Model designed for a	a payer mar	naging 1M lives		\$12800 —	-		
• User dials in their ow	n test utiliz	zation (and test o	costs)	\$12600 —			
DiviTum®TKa modelle	ed at 300-5	00 \$/test		\$12 400 —			

\$12200

\$12000

Before

- Reduction in CT scans and bone scans and futile therapy ٠
- <u>Results</u>: DiviTum[®]TKa savings, ~3 times the investment



Guzauskas G et al, ISPOR 2021 poster

BI ··VICA

Large potential to expand outside initial markets & applications!


Near term market expansion:

- Geographic expansion MBC Europe and Japan
- Locally advanced breast cancer, which adds an additional 30-40% potential on existing markets

Medium term expansion:

- Lung cancer
- Gastrointestinal cancer
- Prostate cancer

Near term/ongoing: Pharma Collaborations - including early and late (CDx) stage drug development



Initial application addresses 1% of people living with cancer!

*) Based on Globocan 2018-data

Summary

- DiviTum®TKa addresses key unmet needs for personalized treatments within metastatic cancer
- Immediate potential of \$ 400-700 M for initial roll-out (MBC in US, Euro-5, Nordics & Japan)
- Strong scientific collaborations and evidence as strong foundation for commercialization process
- Significant potential beyond initial roll-out (30-40% expansion with locally advanced BC)

Upcoming milestones:

- 510(k) approval & US launch (Q3 2021)
- 1st US product reimbursement (2021)
- 1st Euro-5 & Nordic launch by end of 2021

More info: http://biovica.com/investor-relations/analytiker/